TrialFrontiers in immunology2026

TACE plus lenvatinib and envafolimab for conversion therapy in unresectable HCC: a prospective pilot study.

Yuhao Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.